

# Madera Pharmaceuticals

A stylized blue logo symbol consisting of three curved, overlapping lines that form a shape reminiscent of a musical note or a stylized letter 'M'.

---

*Patented Innovative Platform for Transdermal Drug Delivery*



# Introducing Madera Pharmaceuticals

## Patented Innovation in Drug Delivery

- **What is Madera?:** A patented platform enabling transdermal delivery of alprostadil.
- **Why it Matters:** Topical administration offers targeted therapy, avoiding injections and reducing systemic side effects.
- **Market Opportunity:** Multi-billion dollar potential across various therapeutic areas -
  - starting with erectile dysfunction and
  - expanding to broader applications.



Photo by Lucas Vasques on Unsplash

# The Unmet Need in ED Treatment: A \$1B+ Opportunity

## Revolutionizing Erectile Dysfunction Care



### Market Gap

Viagra and Cialis fail in nearly 40% of men and are unsafe for millions with heart conditions.



### High Demand for Non-Invasive Solutions

Current alternatives like Alprostadil injections are effective but invasive; Madera's topical solution eliminates this barrier.



### Projected Market Potential

Madera estimates the unmet ED need exceeds \$1 billion annually.

There are additional broad applications beyond ED.

# Expanding Beyond Erectile Dysfunction

A Platform for Multiple Therapeutic Markets, including -



## Raynaud's Syndrome

Affects 9.3% of women; Madera addresses an unmet need in this growing market.



## Diabetic Ulcers

An estimated \$1.75B market in the U.S. alone, with high demand for non-invasive treatments.



## Women's Sexual Health

80% of post-menopausal women experience issues that could benefit from our transdermal platform.

# Milestones Achieved & The Road Ahead

## A Clear Path to Commercialization and FDA Approval

- **Key Achievements:**
  - US patent granted in 2024
  - Successful animal efficacy and skin permeation testing
- **Next Steps:**
  - Human efficacy trials in 2025
  - Commercialization via compounding pharmacies by 2026
- **Regulatory Pathway:**
  - 503A/503B compounding
  - Streamlined 505(b)(2) pathway with FDA - approval expected within 3 years



Photo by CDC on Unsplash

# Mike Danzi - Lead Investor & CEO

## A Proven Track Record of Transformational Success



- **Biotek Solutions/Ventana Medical:** CEO, took from pre-revenue to IPO, delivering *7x returns at IPO and 25x returns* when acquired by Roche for \$3.4B
- **US Labs:** Founder & CEO, Pioneered targeted cancer diagnostics; *sold to LabCorp for \$155M*
- **ICN Pharmaceuticals** (NYSE:ICN) – Turnaround COO; *3x stock price, \$2 billion value generated*
- **Legacy Pharmaceuticals:** Founder & CEO, *15x investment return*
  
- Named inventor on Madera patent
- Harvard Business School MBA with Distinction
- Cornell Engineering BS Material Science & Engineering
- Veteran, US Navy fast-attack nuclear submarine officer

# Madera Team Strategic Partners

Proven Track Record in Pharmaceutical Innovation, Drug Development and FDA Approvals



**Prof. Marc Brown, PhD**  
World leader in drug development and drug delivery to the skin, nail, eye and airways,



**Charles Evans, PhD**  
Named Inventor on Madera's patent  
  
Specialist in topical and transdermal formulations at MedPharm Ltd.



**Sean Wevrett, PhD**  
Expert in drug formulation at MedPharm.



**Bob Babilon, MS, MBA**  
Expert at Regulatory Affairs and Quality Assurance

# Thank you for considering Madera

- Transdermal Drug Delivery Platform
  - Patented Delivery Method
  - Multiple Large Potential Therapeutic Markets
- 
- Contact Information:  
Mike Danzi, CEO  
949-500-8900  
[MikeDanzi@MaderaPharm.com](mailto:MikeDanzi@MaderaPharm.com)



Photo by Cytonn Photography on Unsplash



## **DISCLAIMER:**

By accepting this material, you hereby agree and acknowledge the following:

This document has been prepared by Madera Pharmaceuticals, Inc. (the “**Company**”) for informational purposes only and for the private use of the recipient. This document is confidential to the Company. Neither this material nor any information that the Company presents in connection herewith may be used, circulated, quoted, or forwarded to any third party and should not be used as a basis for trading in securities of the Company or for any other investment decision.

This document and the analyses contained herein are preliminary in nature and do not constitute an opinion of the Company as to the value of the Company or its prospects, or any related matters. Accordingly, this document should not be relied upon for such purposes. Neither the Company nor any of its respective officers, directors, or employees shall have any liability whatsoever, contingent or otherwise, to you or to third parties for the quality, accuracy, timeliness, continued availability, or completeness of the information made available herein or in any other written or oral communication, nor for any special, indirect, incidental, or consequential damages that may be incurred or experienced because of the use of the information made available herein or therein, even if they have been advised of the possibility of such damages.

This document is not, and under no circumstances should be construed as, an offering memorandum or an advertisement for an offering of securities in the United States or any other jurisdiction. No securities commission or similar authority in the United States has reviewed or in any way passed upon this document or approved or disapproved of the securities described herein.

This document may be amended, superseded, or replaced by the Company at any time. Nothing herein shall be deemed to constitute investment, legal, tax, financial, accounting, or other advice.

## **FORWARD-LOOKING STATEMENTS:**

This presentation includes, and our response to various questions may include forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs.

These forward-looking statements, including regulatory and commercial timelines and market size estimates, among others, are subject to a number of risks, uncertainties, and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, achievements, or events and circumstances reflected in the forward-looking statements will occur. We are under no duty to update any of these forward-looking statements after the date of this presentation to conform these statements to actual results or revised expectations, except as required by law. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

This presentation includes long-term goals that are forward-looking, are subject to significant business, economic, regulatory, and competitive uncertainties and contingencies, many of which are beyond our control and our management’s control, and are based upon assumptions with respect to future decisions, which are subject to change. Actual results will vary and those variations may be material. Nothing in this presentation should be regarded as a representation by any person that these goals will be achieved and we undertake no duty to update our goals.